This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.
Quiz|Articles|May 31, 2026
Dermatology Times Spot Test: May 31, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A weekly quiz series is positioned to reinforce familiarity with essential dermatology topics, practice-relevant trends, and notable breakthroughs.
- This week’s question set emphasizes inflammatory disease, aligning knowledge assessment with recent news coverage.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on this week’s news on
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
What active ingredients are included in the recently FDA-approved Differin Epiduo Acne Gel?
In this school-based sun safety program, awareness that UV exposure can cause skin cancer increased from 55.7% to what percentage immediately after the intervention?
Which additional disease is planned for investigation in a phase 2a study of zumilokibart?
Advertisement
Related to this article
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
The Value of Precision Medicine in Atopic Dermatitis and Skin Cancers
2
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Day 2 Recap: Fall Clinical 2026
5